Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Qiang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5451-4862; OpenAlex author ID A5100409479. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses. Co-author DOI 10.1186/s12885-025-13976-6↗
  2. Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress. Co-author DOI 10.1016/j.intimp.2024.113497↗
  3. Metformin Reverses Radiotherapy-Induced Pancreatic Cancer Cell Senescence by Alleviating the Unfolded Protein Response Last author DOI 10.22541/au.172458216.61587476/v1↗
  4. Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. Co-author DOI 10.1016/j.bcp.2023.115810↗
  5. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  6. Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. Co-author DOI 10.1155/2022/8675096↗
  7. miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Co-author DOI 10.1038/cddis.2017.530↗
  8. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Co-author DOI 10.1186/s12943-017-0723-7↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaofeng Zhang · 3 shared papers, 2023–2025 · strength 0.70
  2. Dongchao Xu · 3 shared papers, 2022–2024 · strength 0.58
  3. Hongzhang Shen · 3 shared papers, 2022–2024 · strength 0.58
  4. Mengyao Tian · 2 shared papers, 2022–2024 · strength 0.39
  5. Hangbin Jin · 1 shared paper, 2025 · strength 0.28
  6. Yuxin Wang · 1 shared paper, 2025 · strength 0.28
  7. Wenjin Xu · 1 shared paper, 2024 · strength 0.22
  8. Meidan Ying · 1 shared paper, 2023 · strength 0.19
  9. Manmei Long · 2 shared papers, 2017 · strength 0.13
  10. Ming Zhan · 2 shared papers, 2017 · strength 0.13
  11. Jian Wang · 2 shared papers, 2017 · strength 0.13
  12. Ruimeng Yang · 2 shared papers, 2017 · strength 0.13
  13. Feng Jiao · 1 shared paper, 2022 · strength 0.11
  14. Yingbin Liu · 1 shared paper, 2022 · strength 0.11
  15. Xiaofei Zhang · 1 shared paper, 2022 · strength 0.11
  16. Tiebo Mao · 1 shared paper, 2022 · strength 0.11
  17. Yu Wang · 1 shared paper, 2022 · strength 0.11
  18. Jiong Hu · 1 shared paper, 2022 · strength 0.11
  19. Yongwei Sun · 1 shared paper, 2022 · strength 0.11
  20. Liwei Wang · 1 shared paper, 2022 · strength 0.11
  21. Jiayu Yao · 1 shared paper, 2022 · strength 0.11
  22. Shumin Li · 1 shared paper, 2022 · strength 0.11
  23. Jiujie Cui · 1 shared paper, 2022 · strength 0.11
  24. Yuexiang Wang · 1 shared paper, 2022 · strength 0.11
  25. Deliang Fu · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.